- Home
- IMUX vs CRDL Comparison
IMUX vs CRDL Comparison
Compare IMUX & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- CRDL
- Stock Information
- Founded
- IMUX 2016
- CRDL 2017
- Country
- IMUX United States
- CRDL Canada
- Employees
- IMUX N/A
- CRDL N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IMUX Health Care
- CRDL Health Care
- Exchange
- IMUX Nasdaq
- CRDL Nasdaq
- Market Cap
- IMUX 92.2M
- CRDL 90.4M
- IPO Year
- IMUX N/A
- CRDL N/A
- Fundamental
- Price
- IMUX $0.72
- CRDL $1.01
- Analyst Decision
- IMUX Strong Buy
- CRDL Strong Buy
- Analyst Count
- IMUX 5
- CRDL 2
- Target Price
- IMUX $7.00
- CRDL $9.00
- AVG Volume (30 Days)
- IMUX 1.4M
- CRDL 702.0K
- Earning Date
- IMUX 11-06-2025
- CRDL 11-12-2025
- Dividend Yield
- IMUX N/A
- CRDL N/A
- EPS Growth
- IMUX N/A
- CRDL N/A
- EPS
- IMUX N/A
- CRDL N/A
- Revenue
- IMUX N/A
- CRDL N/A
- Revenue This Year
- IMUX N/A
- CRDL N/A
- Revenue Next Year
- IMUX N/A
- CRDL N/A
- P/E Ratio
- IMUX N/A
- CRDL N/A
- Revenue Growth
- IMUX N/A
- CRDL N/A
- 52 Week Low
- IMUX $0.56
- CRDL $0.77
- 52 Week High
- IMUX $1.42
- CRDL $2.24
- Technical
- Relative Strength Index (RSI)
- IMUX 37.43
- CRDL 40.22
- Support Level
- IMUX $0.67
- CRDL $1.14
- Resistance Level
- IMUX $0.87
- CRDL $1.15
- Average True Range (ATR)
- IMUX 0.05
- CRDL 0.08
- MACD
- IMUX -0.01
- CRDL -0.01
- Stochastic Oscillator
- IMUX 21.92
- CRDL 8.55
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.